Novo Nordisk (Copenhagen: NOVO B) reported that oral semaglutide reduced HbA1c by 0.83% versus placebo at 26 weeks in children and adolescents with type 2 diabetes, positioning the drug as a potential first oral GLP-1 receptor agonist approved for this age group.
PIONEER TEENS is a 52-week, randomized, double-blind, placebo-controlled Phase III trial enrolling 132 participants aged 10–17 years with type 2 diabetes on background metformin, basal insulin, or both.
The primary endpoint — change from baseline HbA1c at week 26 — showed a statistically significant and superior reduction of 0.83% in favor of oral semaglutide over placebo. The company described the safety profile as consistent with prior semaglutide trials in adults, though no numerical adverse event data were disclosed in the topline release.
Oral semaglutide activates the GLP-1 receptor, driving glucose-dependent insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. The drug is already approved for adults as Rybelsus in the US and EU; a US launch under the Ozempic pill branding is expected later in Q2 2026. Current pediatric type 2 diabetes guidelines recommend metformin and insulin as first-line options, but metformin is associated with glycemic control failure in roughly half of adolescents, and insulin carries risks of hypoglycemia and weight gain. No oral GLP-1 agonist is currently approved for patients under 18. Cross-trial comparisons are limited, but injectable semaglutide and liraglutide have shown efficacy in adolescent obesity and, in liraglutide's case, pediatric type 2 diabetes, providing some mechanistic precedent for GLP-1 activity in this population.
Novo Nordisk said it expects to file for regulatory approval of a pediatric label expansion in both the US and EU in the second half of 2026.
Spot something wrong? Report an issue with this article